Cargando…

Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study

PURPOSE: This study aimed to evaluate clinical pharmacist’s contribution to the pneumococcal vaccination rate by providing education to cancer patients in hospital settings. METHODS: This study was conducted in 2 tertiary-care hospitals’ medical oncology outpatient clinics. Patients over 18 years of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozdemir, Nesligul, Aktas, Burak Y., Gulmez, Ahmet, Inkaya, Ahmet C., Bayraktar-Ekincioglu, Aygin, Kilickap, Saadettin, Unal, Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975445/
https://www.ncbi.nlm.nih.gov/pubmed/36856870
http://dx.doi.org/10.1007/s00520-023-07652-3
_version_ 1784898874967588864
author Ozdemir, Nesligul
Aktas, Burak Y.
Gulmez, Ahmet
Inkaya, Ahmet C.
Bayraktar-Ekincioglu, Aygin
Kilickap, Saadettin
Unal, Serhat
author_facet Ozdemir, Nesligul
Aktas, Burak Y.
Gulmez, Ahmet
Inkaya, Ahmet C.
Bayraktar-Ekincioglu, Aygin
Kilickap, Saadettin
Unal, Serhat
author_sort Ozdemir, Nesligul
collection PubMed
description PURPOSE: This study aimed to evaluate clinical pharmacist’s contribution to the pneumococcal vaccination rate by providing education to cancer patients in hospital settings. METHODS: This study was conducted in 2 tertiary-care hospitals’ medical oncology outpatient clinics. Patients over 18 years of age and diagnosed with cancer for less than 2 years, in remission stage, and have not previously received the pneumococcal vaccine were included. Patients were randomized to intervention and control groups. The intervention group was provided vaccination education and recommended to receive the PCV13 vaccine. The control group received routine care. Patients’ knowledge about pneumonia/pneumococcal vaccine, Vaccine Attitude Examination Scale (VAX) score, and vaccination rates were evaluated at baseline and 3 months after the education. RESULTS: A total of 235 patients (intervention: 117, control: 118) were included. The mean age ± SD was 57.86 ± 11.88 years in the control and 60.68 ± 11.18 years in the intervention groups. The numbers of correct answers about pneumonia/pneumococcal vaccine (p = 0.482) and VAX scores (p = 0.244) of the groups were similar at baseline. After the intervention, the median (IQR) number of correct answers in intervention group [10(3)] was higher than control group [8(4)] (p < 0.001). After the education, the total VAX score (mean ± SD) was less in intervention group (33.09 ± 7.018) than the control group (36.07 ± 6.548) (p = 0.007). Three months after the education, 20.2% of the patients in the intervention and 6.1% in the control groups were vaccinated with pneumococcal vaccine (p = 0.003). CONCLUSIONS: The pneumococcal vaccination rate in cancer patients has increased significantly by the education provided by a clinical pharmacist in hospital settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07652-3.
format Online
Article
Text
id pubmed-9975445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99754452023-03-01 Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study Ozdemir, Nesligul Aktas, Burak Y. Gulmez, Ahmet Inkaya, Ahmet C. Bayraktar-Ekincioglu, Aygin Kilickap, Saadettin Unal, Serhat Support Care Cancer Research PURPOSE: This study aimed to evaluate clinical pharmacist’s contribution to the pneumococcal vaccination rate by providing education to cancer patients in hospital settings. METHODS: This study was conducted in 2 tertiary-care hospitals’ medical oncology outpatient clinics. Patients over 18 years of age and diagnosed with cancer for less than 2 years, in remission stage, and have not previously received the pneumococcal vaccine were included. Patients were randomized to intervention and control groups. The intervention group was provided vaccination education and recommended to receive the PCV13 vaccine. The control group received routine care. Patients’ knowledge about pneumonia/pneumococcal vaccine, Vaccine Attitude Examination Scale (VAX) score, and vaccination rates were evaluated at baseline and 3 months after the education. RESULTS: A total of 235 patients (intervention: 117, control: 118) were included. The mean age ± SD was 57.86 ± 11.88 years in the control and 60.68 ± 11.18 years in the intervention groups. The numbers of correct answers about pneumonia/pneumococcal vaccine (p = 0.482) and VAX scores (p = 0.244) of the groups were similar at baseline. After the intervention, the median (IQR) number of correct answers in intervention group [10(3)] was higher than control group [8(4)] (p < 0.001). After the education, the total VAX score (mean ± SD) was less in intervention group (33.09 ± 7.018) than the control group (36.07 ± 6.548) (p = 0.007). Three months after the education, 20.2% of the patients in the intervention and 6.1% in the control groups were vaccinated with pneumococcal vaccine (p = 0.003). CONCLUSIONS: The pneumococcal vaccination rate in cancer patients has increased significantly by the education provided by a clinical pharmacist in hospital settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07652-3. Springer Berlin Heidelberg 2023-03-01 2023 /pmc/articles/PMC9975445/ /pubmed/36856870 http://dx.doi.org/10.1007/s00520-023-07652-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Ozdemir, Nesligul
Aktas, Burak Y.
Gulmez, Ahmet
Inkaya, Ahmet C.
Bayraktar-Ekincioglu, Aygin
Kilickap, Saadettin
Unal, Serhat
Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title_full Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title_fullStr Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title_full_unstemmed Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title_short Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
title_sort impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975445/
https://www.ncbi.nlm.nih.gov/pubmed/36856870
http://dx.doi.org/10.1007/s00520-023-07652-3
work_keys_str_mv AT ozdemirnesligul impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT aktasburaky impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT gulmezahmet impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT inkayaahmetc impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT bayraktarekinciogluaygin impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT kilickapsaadettin impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy
AT unalserhat impactofpharmacistlededucationalinterventiononpneumococcalvaccinationratesincancerpatientsarandomizedcontrolledstudy